HighVista Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

HighVista Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,551	Closed	-$427K	–	141
2024 Q3	$427K	Sell	1,551 -1,051	-40%	-$274K	0.15%	136
2024 Q2	$632K	Buy	+2,602	New	+$411K	0.23%	112
2023 Q3	–	Sell	-4,056	Closed	-$770K	–	134
2023 Q2	$770K	Hold	4,056	–	–	0.35%	72
2023 Q1	$812K	Hold	4,056	–	–	0.66%	47
2022 Q4	$964K	Sell	4,056 -183	-4%	-$39K	0.57%	46
2022 Q3	$848K	Sell	4,239 -749	-15%	-$143K	0.48%	50
2022 Q2	$728K	Sell	4,988 -567	-10%	-$80.4K	0.44%	53
2022 Q1	$907K	Sell	5,555 -1,538	-22%	-$234K	0.58%	42
2021 Q4	$1.2M	Buy	7,093 +935	+15%	+$174K	0.96%	33
2021 Q3	$1.16M	Buy	+6,158	New	+$1.16M	0.77%	40
2020 Q3	–	Sell	-2,805	Closed	-$415K	–	117
2020 Q2	$415K	Buy	+2,805	New	+$378K	0.34%	55

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

HighVista Strategies's ALNY Position: Q4 2024 in Review

HighVista Strategies sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 1,551 shares — an estimated $427K sold.

HighVista Strategies first reported a position in ALNY in Q2 2020 and held it in 11 quarters. The position peaked at $1.2M in Q4 2021. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

HighVista Strategies reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
HighVista Strategies sold 1,551 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $427K.
HighVista Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 11 quarters.
HighVista Strategies's Alnylam Pharmaceuticals position peaked at $1.2M in Q4 2021.
595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on HighVista Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.